You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Most of the world is happily witnessing a decline in the burden of COVID-19 disease after the global efforts to develop, produce, and deploy anti-SARS-CoV2 vaccines to massive country-level vaccination campaigns. At the same time, this decline is coming at the cost of a silent public crisis due to the rise in the number of people suffering from the post-COVID-19 syndrome (commonly known as long COVID). These people experience a wide set of symptoms, such as persistent fatigue, post-exertional malaise after minimal physical or mental effort, and unrefreshing sleep, representing a substantial healthcare burden worldwide. Some of these people also comply with the current criteria for the diagnosis of Chronic Fatigue Syndrome (CFS), a complex disease often stigmatized by society and neglected by research funders over the years.
Acute respiratory distress syndrome (ARDS) and sepsis remain leading causes of patient morbidity and mortality and the COVID-19 pandemic has highlighted the continuing lack of effective therapeutic options for these and other related acute inflammatory conditions. Recently, a host of novel medicinal approaches have been investigated to address this problem, such as advances in the development of pharmacological agents, recombinant protein drugs and cell and gene therapies. Bioinformatics based approaches and clinical profiling of patients are also paving the way for stratification, targeted therapies and precision medicines. Given recent exciting work in this field, this is a timely opportunity to showcase exciting advances in the field of critical care medicine, particularly those relying on paradigm shifting modalities and outside-the-box approaches to address this family of devastating conditions.